GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cambium Bio Ltd (ASX:CMB) » Definitions » Liabilities-to-Assets

Cambium Bio (ASX:CMB) Liabilities-to-Assets : 13.32 (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Cambium Bio Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Cambium Bio's Total Liabilities for the quarter that ended in Dec. 2023 was A$1.19 Mil. Cambium Bio's Total Assets for the quarter that ended in Dec. 2023 was A$0.09 Mil. Therefore, Cambium Bio's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2023 was 13.32.


Cambium Bio Liabilities-to-Assets Historical Data

The historical data trend for Cambium Bio's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cambium Bio Liabilities-to-Assets Chart

Cambium Bio Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Liabilities-to-Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.51 1.04 0.54 0.58 1.05

Cambium Bio Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.46 0.58 1.78 1.05 13.32

Competitive Comparison of Cambium Bio's Liabilities-to-Assets

For the Biotechnology subindustry, Cambium Bio's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cambium Bio's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cambium Bio's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Cambium Bio's Liabilities-to-Assets falls into.



Cambium Bio Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Cambium Bio's Liabilities-to-Assets Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Liabilities-to-Assets (A: Jun. 2023 )=Total Liabilities/Total Assets
=2.589/2.464
=1.05

Cambium Bio's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2023 is calculated as

Liabilities-to-Assets (Q: Dec. 2023 )=Total Liabilities/Total Assets
=1.185/0.089
=13.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cambium Bio  (ASX:CMB) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Cambium Bio Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Cambium Bio's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Cambium Bio (ASX:CMB) Business Description

Traded in Other Exchanges
N/A
Address
16 Goodhope Street, Paddington, Sydney, NSW, AUS, 2021
Regeneus Ltd is a clinical-stage regenerative medicine company in Australia. It mainly develops a portfolio of cell-based therapies to address unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology diseases. The company uses stem cell and immuno-oncology technologies to develop cell-based therapies. Its product pipeline consists of two platform technologies, Progenza and Sygenus, across three target therapeutic areas namely osteoarthritis, neuropathic pain, and skin wound healing. The company has one operating segment being the development of innovative cell-based therapies to address significant unmet medical needs in human and veterinary health.

Cambium Bio (ASX:CMB) Headlines

No Headlines